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S188 Oral PresentationsIn NOD/SCID-b2-microglobulinnull (NSb) mice, human
ALDHbr cells also established short-term human myeloid develop-
ment, including CD41+ platelets. In contrast, engraftment by total
CB was very low. However, human hematopoietic chimerism in-
creased .10-fold when total CB was augmented 4 hours later with
ALDHbr progenitors. By using HLA-matched (6/6), but sex-
mismatched CB, continuing studies will examine the relative contri-
butions of the ALDHbr cells and the total CB.
Unmanipulated CB did not yield efficient short-term myeloid en-
graftment in either NOD/SCID strain. In contrast, ALDHbr pro-
genitors established human myeloid development in both strains.
Furthermore, ALDHbr cells altered the outcome of CB transplants
in two distinct ways. In NSg mice, the ALDHbr progenitors facili-
tated either the engraftment or the proliferation of T cells. In NSb
mice, ALDHbr progenitors appeared to directly augment short-
term myeloid engraftment by total CB. Importantly, the latter stud-
ies reflect the clinical experience of early CBT trials that use this
strategy.
Hematopoietic chimerism in NSg and NSbmice
NOD/SCID Chimerism,
strain Graft %huCD4516 SD CompositionNSg ALDHbr 126 4.9% (n5 5) Myeloid and B cells
NSg CB 7.46 4.7% (n5 8) T cells
NSg CB 1ALDHbr 18.96 9.3% (n5 10) T cells
NSb ALDHbr 5.66 4.7% (n5 5) Myeloid and B cells
NSb CB 0.326 0.19% (n5 4) \detection limit
NSb CB 1ALDHbr 4.36 1.9% (n5 5) Myeloid and B cellsFor each mouse strain, the level of human hematopoietic chimerism
achieved within the bone marrow is provided for each cohort. The gen-
eral composition of the human progeny within the bone marrow is also
given.SUPPORTIVE CARE
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IMPROVIT STUDY WITH ONE YEAR FOLLOW UP
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Background: IFI are significant causes of morbidity and death af-
ter HCT. Optimal antifungal prophylaxis following HCT is un-
certain. The potential of oral voriconazole required prospective
randomized evaluation. Itraconazole oral solution is a mold-active
agent with evidence for efficacy and documented safety in HCT
patients.
Methods: Prospective, open-label, multicenter study for primary
IFI prophylaxis after allogeneic HCT. Patients .5 12 years
were randomized (stratified by conditioning regimen intensity
and donor type) to receive oral voriconazole or oral itraconazole
from the day of HCT for at least 100 and up to 180 days. Pri-
mary composite endpoint was success of prophylaxis at Day
180, i.e. patient survived without developing proven/probable
IFI or discontinuing prophylaxis for.14 days during the
first 100 days. The study was powered to demonstrate non-
inferiority at day 180. If non-inferiority was shown, superiority
was tested.Results: 234 patients were randomized and treated with vorico-
nazole and 255 with itraconazole; all received.1 dose of study
drug. Success of prophylaxis was significantly higher with vori-
conazole than with itraconazole at Days 100 (55% vs 41%; ad-
justed for conditioning regimen and relatedness of donor 95%
CI for difference: 6%, 24%; p5 0.0007) and 180 (49% vs
35%; adjusted 95% CI for difference: 7%, 24%; p5 0.0004).
Significantly more voriconazole than itraconazole (54% vs
40%; p5 0.0014) patients had sufficient days of prophylaxis
(median: 97 vs 68 days). IFI incidence was low in both arms
(voriconazole: 1.3%, itraconazole: 2.4%); no patients developed
IFI while receiving voriconazole, compared with 3 itraconazole
patients (p5 0.08). There was no difference in survival at Day
100 and 180 (94% and 85% in both arms at respective time-
points). 1-year survival was 75% and 69% in voriconazole
and itraconazole arms respectively (p5 0.1256 for the difference
in proportions). The most common treatment-related adverse
events for voriconazole and itraconazole, respectively, were
vomiting (4% vs 16%), nausea (8% vs 15%), diarrhea (4% vs
11%), hepatotoxicity/liver function test abnormalities (12% vs
5%) and visual impairment (6% vs 0%) (p\5 0.01 for all com-
parisons).
Conclusions: Success of prophylaxis was significantly higher with
voriconazole than itraconazole. Primary prophylaxis with voricona-
zole is an effective, safe option for preventing IFI after allogeneic
HCT.
IFIs during study
Treatment Body Site
EORTC criteria Emergent* Pathogen of IFI3 in Voriconazole arm
Proven No Candida krusei Blood
Proven No Candida parapsilosis Blood
Probable No Aspergillus fumigatus Lung6 in Itraconazole arm
Proven Yes Candida glabrata Blood
Proven No Aspergillus fumigatus Lung
Probable Yes Aspergillus sp Lung
Probable Yes Aspergillus sp Lung
Probable No Aspergillus fumigatus Lung
Probable No Aspergillus sp LungTreatment-emergent IFIs: Voriconazole 0%, Itraconazole 1.2% (p5 0.08 for
difference).
*Treatment-emergent IFIs: occurring any time while patient was on
study drug and for 7 days following treatment discontinuation.90
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Background: Although screening of patients’ vital organ function
is routinely performed prior to autologous or allogeneic hemato-
poietic stem cell transplantation (HSCT), the lowest acceptable
threshold for function is not well defined. As a consequence, pa-
tients with significant organ dysfunction are often excluded from
transplantation. In order to make transplantation an option for
the maximum number of patients, retrospective studies have
been conducted to determine the impact of organ dysfunction
on transplantation outcome. The implication of transplanting pa-
tients with coronary artery disease (CAD) is one such area for
which there is no published data.
Oral Presentations S189Methods: A retrospective review of the medical records of alloge-
neic and autologous HSCT recipients transplanted at Memorial
Sloan Kettering Cancer Center between January 1997 and Decem-
ber 2006 was performed. A history of CAD included$ 1 of the fol-
lowing: coronary revascularization (PCI), coronary artery bypass
grafting surgery (CABG), obstructive CAD by catheterization
(.50% stenosis), ischemia by stress testing or documented history
of myocardial infarction (MI).
Results: Results are summarized in the table. 715 patients, age
40 years or older, who underwent 750 HSCTs were identified.
67% received autologous and 33% allogeneic HSCT. 46 pa-
tients who underwent 48 transplants were confirmed to have
CAD: 41% had a history of MI, 48% PCI, 24% CABG and
11% a positive stress test alone. Patients with CAD were
more often males who were older at transplant. Diabetes and
hypercholesterolemia were more prevalent in the CAD group.
Smoking history and hypertension were not significantly differ-
ent. There was no difference in cancer type or in protocol.
All-cause death during transplantation and death at one year
were the same, as was urgent admission to the ICU. The aver-
age length of stay was significantly longer in the control group
than in the CAD group, due to outliers in the control group.
Cardiac complications, including arrhythmias, myocardial infarc-
tion and new cardiomyopathy, were uncommon and did not oc-
cur more frequently in the CAD group than in the control
group.
Conclusions: This study demonstrates that patients with concur-
rent CAD can be safely transplanted, even with ablative regimens.
Pre-transplantation screening likely imposes a selection bias for pa-
tients with less severe CAD.
Characteristics and outcomes for CAD patients vs. controls
CAD (%) Control (%) p-valueNumber of Patients 46 669
Autologous/Allogeneic 36 (75) /
12 (25)
470 (67) /
232 (33)0.27Ablative/Nonablative 45 (94) /
3 (6)641 (91) /
61 (9)0.79Male 40 (83) 410 (58) 0.001*
Age at transplant ±
SE in yrs61.756 0.91 55.056 0.31 \0.001*Diabetes mellitus 7 (22) 44 (7) 0.038*
Hypercholesterolemia 22 (48) 132 (20) \0.001*
Smoking 23 (50) 275 (41) 0.279
Hypertension 14 (30) 185 (28) 0.734
Death during
transplant1 (2) 42 (6) 0.514Deaths at 1yr 8 (17) 130 (19) 0.849
ICU admission 6 (13) 68 (10) 0.460
Cardiac events 5 (11) 32 (5) 0.080
Length of hospital
stay in days24.176 1.35 29.506 0.79 0.001**p\0.05, p-value calculated for continuous variables using the t-Test
and for categorical variables using the Fisher’s Exact test.CRA – DATA MANAGEMENT ORAL
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Background: Laboratory ‘‘events’’ go by different names, such as
Error, Accident, Incident, Occurrence or Deviation to name a few.
Reporting of events in the hospital setting is generally well defined
but those occurring in CPF are as yet not classified, though some
of these are mandatory FDA-reportable.
FACT Standards offer definitions for four events: Biological
Product Deviation (BPD) relates to product contamination; Er-
rors and Accidents relate to product safety, purity and potency;
Variance refers to planned deviation from operating procedure;
and Adverse Event refers to any event related to an interven-
tion.
FDA on the other hand has only one broad concern: Prevention
of introduction, transmission, and spread of communicable dis-
ease through a distributed HCT/P; resulting in HCT/P deviation
or an Adverse Reaction (and both are listed together under
Complaint).
However in the CPF daily routine, we come across a number of
events which are not covered by FACTor FDA regulatory standards,
but which must be addressed if our goal is to improve the quality,
efficiency and safety of the laboratory, its patient, product and
personnel.
Thus far no work has been published referring to events in the
CPF. We at NMH are defining a system for Event Management
which may be worth looking at.
Event Classification: See Table 1.
Discussion: Published data on errors occurring hospital-wide
concur that, Errors are much more frequent than reported Ad-
verse Events (and may be as many as 100:1)1,2; At most times,
Management is unaware of the magnitude of the problem2;
Event-reporting systems may be able to produce valuable
information1,2; Humans are fallible and errors are to be ex-
pected3,4,5; and Errors result from system failures, not people
failures2,3, and 5.
In all likelihood CPF has many events which go unidentified and
unreported in the absence of a standardized system for documenting
events1,2. Further, events go unreported out of fear of embarrass-
ment, punishment or litigation6 or of reprisal, loss of reputation,
job or extra work7 and from lack of belief that reporting will lead
to improvement8.
Conclusion:When CPF events are documented accurately and em-
ployees assured of no punitive action, it may be possible to analyze
and trend events to their source; and implement corrective and
preventive measures to help reduce them over time, leading to over-
all improvement in CPF working, quality, efficiency and patient
safety.
Event Classification
1. HCT/P Deviation:
1.1 BPD: (Distributed, Contaminated,
Recall, Adverse Reaction etc)
1.2 Improper Product Release
(UMN, Without Review or
Signature etc)1.3 Product Label related
1.4 Product Bag related
1.5 Patient-Donor Information
related
1.6 Other: (Improper Processing,
Storage etc)
2. SOP Deviation:
2.1 Not Per Procedure, or No Procedure
2.2 Wrong Procedure or Form
2.3 In-process Label related:2.3 A Wrong or No Label
2.3 B Wrong, No or Incomplete2.4 Data Related:
2.4 A Wrongor No Data or Calculation
2.4 B No or Poor Verification(Continued )
